You are here
Safety, Efficacy Trial Begins for Avanafil in Erectile Dysfunction
"Our development program for avanafil continues to move ahead on schedule with initiation of this Phase 2 study," said John Dietrich vice president of Research and Development at Vivus. "One of the primary goals of this study is to confirm the appropriate dose range in a large group of patients. In addition to this Phase 2 safety and efficacy study, Vivus will initiate drug interaction studies with avanafil later this year and anticipates completing Phase 2 development in 2005."
In March 2001, VIVUS announced it had licensed avanafil, a fast-acting, highly selective, phosphodiesterase type 5 (PDE5) inhibitor from Tanabe Seiyaku Co. Ltd. a Japanese pharmaceutical company. Vivus plans to present additional, peer-reviewed results from a recently completed Phase 2 at-home study comparing avanafil to Pfizer's Viagra(R) (sildenafil) at the Western Sectional meeting of the American Urological Association (AUA) in August 2004.
Source: Vivus, Inc.